Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.48 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3390316 | 0.98 | ZDHHC20 (0.47) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| Sulfuric Acid SCHEMBL6812276 | 0.93 | ZDHHC20 (0.47) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL4653768 | 0.89 | ZDHHC20 (0.55) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL2151789 | 0.81 | TSHR (0.52) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL6283366 | 0.79 | ZDHHC20 (0.52) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL1323810 | 0.79 | ALDH1A1 (0.50) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL4387233 | 0.78 | ZDHHC20 (0.47) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL12731248 | 0.78 | ZDHHC20 (0.50) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL4080615 | 0.77 | TSHR (0.43) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 | |
| SCHEMBL24932662 | 0.76 | ZDHHC20 (0.48) | ZDHHC20ZDHHC2TSHRALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0119109-B2 | CATIONIC AQUEOUS DISPERSIONS OF SYNTHETIC POLYMERS | RHONE-POULENC CHIMIE (FR) | 1991-06-19 | — | — | EP | claimed |
| US-4857585-A | CATIONIC ACRYLIC POLYMERS | RHONE-POULENC SPECIALITIES CHIMIQUES (FR) | 1989-08-15 | — | — | US | claimed |
| EP-0118326-B1 | STABLE AMPHOTERIC LATICES FROM CONJUGATED DIENES | RHONE-POULENC CHIMIE (FR) | 1987-07-01 | — | — | EP | claimed |
| EP-0119109-B1 | CATIONIC AQUEOUS DISPERSIONS OF SYNTHETIC POLYMERS | RHONE-POULENC CHIMIE (FR) | 1987-07-01 | — | — | EP | claimed |
| EP-0118327-B1 | CATIONIC LATICES FROM CONJUGATED DIENES | RHONE-POULENC CHIMIE (FR) | 1987-04-22 | — | — | EP | claimed |
| EP-0120720-B1 | STABLE AND AMPHOTERIC AQUEOUS DISPERSION OF SYNTHETIC POLYMERS | RHONE-POULENC CHIMIE (FR) | 1987-04-08 | — | — | EP | claimed |
| US-4528322-A | Aqueous cationic dispersions of synthetic polymers | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1985-07-09 | — | — | US | claimed |
| EP-0120720-A1 | Stable and amphoteric aqueous dispersion of synthetic polymers | RHONE-POULENC CHIMIE (FR) | 1984-10-03 | — | — | EP | claimed |
| EP-0119109-A1 | Cationic aqueous dispersions of synthetic polymers | RHONE-POULENC CHIMIE (FR) | 1984-09-19 | — | — | EP | claimed |
| EP-0118327-A1 | Cationic latices from conjugated dienes | RHONE-POULENC CHIMIE (FR) | 1984-09-12 | — | — | EP | claimed |
| EP-0118326-A1 | Stable amphoteric latices from conjugated dienes | RHONE-POULENC CHIMIE (FR) | 1984-09-12 | — | — | EP | claimed |
| US-11607407-B2 | Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use | RELMADA THERAPEUTICS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| CN-107115326-B | Skin pharmaceutical composition of 1-methyl-N- (2, 6-xylyl) -2-piperidine formamide and using method thereof | 雷尔玛达治疗股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| EP-2557924-B1 | DERMAL PHARMACEUTICAL COMPOSITIONS OF 1-METHYL-2',6'-PIPECOLOXYLIDIDE AND METHOD OF USE | RELMADA THERAPEUTICS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20170333410-A1 | Dermal Pharmaceutical Compositions of 1-Methyl-2',6'-Pipecoloxylidide and Method of Use | RELMADA THERAPEUTICS, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-4528322-A | Aqueous cationic dispersions of synthetic polymers | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1985-07-09 | — | — | US | disclosed |
| EP-0120720-A1 | Stable and amphoteric aqueous dispersion of synthetic polymers | RHONE-POULENC CHIMIE (FR) | 1984-10-03 | — | — | EP | disclosed |
| EP-0119109-A1 | Cationic aqueous dispersions of synthetic polymers | RHONE-POULENC CHIMIE (FR) | 1984-09-19 | — | — | EP | disclosed |
| EP-0118326-A1 | Stable amphoteric latices from conjugated dienes | RHONE-POULENC CHIMIE (FR) | 1984-09-12 | — | — | EP | disclosed |
| EP-0118327-A1 | Cationic latices from conjugated dienes | RHONE-POULENC CHIMIE (FR) | 1984-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333410-A1 | Dermal Pharmaceutical Compositions of 1-Methyl-2',6'-Pipecoloxylidide and Method of Use | PIP4K2C, PIP5K1C, PIP4K2A | ZDHHC20 607/4885ZDHHC2 1105/4885TSHR 4874/4885 |
| US-11607407-B2 | Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use | PIP4K2C, PIP5K1C, PIP4K2A | ZDHHC20 579/4885ZDHHC2 1036/4885TSHR 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.